文献速递心境障碍

围产期别孕烷醇酮血药浓度与抑郁症状:系统综述与个体参与者数据荟萃分析

Peripartum allopregnanolone blood concentrations and depressive symptoms: a systematic review and individual participant data meta-analysis.
PubMed 文献 · Mol Psychiatry · 2024-11-07

该系统综述与个体参与者数据荟萃分析检索至2024年7月,纳入13项研究共2509名女性(其中849名有围产期抑郁症状),比较孕中期、孕晚期及产后各时间点别孕烷醇酮血药浓度。主要分析显示有无围产期抑郁症状的女性在各时间点别孕烷醇酮浓度均无显著差异(p>0.05),但亚组分析在孕21-24周和25-28周发现症状组浓度较高。

要点

  • 有无围产期抑郁症状的女性在各时间点别孕烷醇酮浓度均无显著差异(p>0.05)。
  • 孕21-24周和25-28周亚组中,有症状组别孕烷醇酮浓度高于无症状组(SMD=1.07和0.92)。
  • 研究间在围产期时间点、队列、抑郁测量和分析方法上的异质性阻碍了进展。

核心结论

  • 围产期抑郁症状与别孕烷醇酮浓度差异无关。

研究设计与样本

  • 系统综述检索PubMed/Embase/PsychInfo/Cinhail至2023年8月(2024年7月更新),方案注册于PROSPERO(CRD42022354495)。
  • 纳入13项研究共2509名女性,其中849名有围产期抑郁症状,采用随机效应模型计算标准化均数差(SMD)及95%CI。
  • 采用Newcastle-Ottawa量表评估研究质量,2项研究评为差、1项良好、10项一般。

主要发现

  • 有无围产期抑郁症状的女性在孕中期、孕晚期及产后各时间点别孕烷醇酮浓度均无显著差异(p>0.05)。
  • 孕期评估的别孕烷醇酮浓度在产后随访时有无抑郁症状的女性间无显著差异(p>0.05)。
  • 孕21-24周有症状组别孕烷醇酮浓度高于无症状组(SMD=1.07,95%CI=0.04,2.11)。
  • 孕25-28周有症状组别孕烷醇酮浓度高于无症状组(SMD=0.92,95%CI=0.26,1.59)。
  • 孕25-28周使用质谱联合色谱法与免疫测定法的研究间存在差异(p=0.01),孕21-24周血浆与血清样本的研究间存在差异(p=0.005)。

局限性

  • 研究质量评为差、良好和一般的研究分别为2项、1项和10项。
  • 围产期时间点、研究队列、抑郁症状测量和分析方法的异质性阻碍了阐明与围产期抑郁症状相关的神经活性类固醇信号传导的进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neuroactive steroids including allopregnanolone are implicated in the pathophysiology of peripartum depressive symptoms (PDS). We performed a systematic review searching PubMed/Embase/PsychInfo/Cinhail through 08/2023 (updated in 07/2024), and conducted a random-effects meta-analysis of studies comparing allopregnanolone blood concentrations in women with versus without PDS at various timepoints during the 2nd and 3rd trimester and the postpartum period, calculating standardized mean differences (SMDs) and 95% confidence intervals (CIs). Meta-regression and subgroup analyses included age, diagnoses of affective disorders before pregnancy, antidepressant treatment, analytical methods, and sample type. Study quality was assessed using the Newcastle-Ottawa-scale. The study protocol was registered on PROSPERO (registration number CRD42022354495). We retrieved 13 studies with 2509 women (n = 849 with PDS). Allopregnanolone concentrations did not differ between women with versus without PDS at any timepoint (p > 0.05). Allopregnanolone concentrations assessed during pregnancy did not differ for women with versus without PDS at postpartum follow-up (p > 0.05). Subgroup analyses indicated higher allopregnanolone concentrations in women with versus without PDS at gestational weeks 21-24 and 25-28 (SMD = 1.07, 95% CI = 0.04, 2.11 and SMD = 0.92, 95% CI = 0.26, 1.59 respectively). Moreover, we reported differences between studies using mass-spectrometry combined with chromatography versus immunoassays at gestational weeks 25-28 (p = 0.01) and plasma versus serum samples at gestational weeks 21-24 (p = 0.005). Study quality was rated as poor, good, and fair for two, one and ten studies respectively. PDS were not associated with differences for allopregnanolone concentrations. The use of heterogenous peripartum time points, study cohorts, depression symptom measures and analytical methods has hampered progress in elucidating neuroactive steroid signaling linked to PDS.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schoretsanitis G, Osborne LM, Sundström-Poromaa I, et al. Peripartum allopregnanolone blood concentrations and depressive symptoms: a systematic review and individual participant data meta-analysis. Mol Psychiatry. 2024. PMID: 39511449. doi:10.1038/s41380-024-02747-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。